Latham Advises Novavax on Sale of Its Manufacturing Campus to Novo Nordisk

Latham & Watkins has advised Novavax, a global biotechnology company developing vaccines to address serious infectious diseases, on the proposed sale of its manufacturing campus located in Bohumil, Jevany, Czech Republic, to Novo Nordisk, a leading global healthcare company. The transaction, valued at approximately US$200 million, includes the proposed sale of a 150,000-square foot state-of-the-art recombinant protein manufacturing facility with support buildings, along with the transfer of the existing workforce and all related and required infrastructure. Closing of the transaction is subject to the decision of the State Institute for Drug Control of the Czech Republic. 

The Latham team was led by London corporate partners Robbie McLaren and Melanie Howard, with associate Stuart McRobbie. Advice on regulatory matters was provided by Paris partner Eveline Van Keymeulen, with associate Jeanne Fabre; on DTT matters by London partner Christian McDermott, with New York counsel Eliot Choy and London associate Oscar Bjartell; on tax matters by London partner Simon Skinner, with associate Catherine Hill; on employment matters by London partner Sarah Gadd, with associate Chris Wilkinson; and on ESG matters by London partner Paul Davies, with counsel Michael Green. Local counsel to Novavax was provided by Novalia.